Nörodejeneratif Hastalıklarda Diş Hamuru Kök Hücrelerinin Özellikleri ve Terapötik Potansiyeli.
Characteristics and Therapeutic Potential of Dental Pulp Stem Cells on Neurodegenerative Diseases.
DOI: 10.3389/fnins.2020.00407PMID: 32457568
Characteristics and Therapeutic Potential of Dental Pulp Stem Cells on Neurodegenerative Diseases.
DOI: 10.3389/fnins.2020.00407PMID: 32457568
Speech and Language Therapy for Voice Problems in Parkinson's Disease: A Meta-Analysis.
DOI: 10.1176/appi.neuropsych.19020044PMID: 32374650
Microglia depletion prior to lipopolysaccharide and paraquat treatment differentially modulates behavioral and neuronal outcomes in wild type and G2019S LRRK2 knock-in mice.
DOI: 10.1016/j.bbih.2020.100079PMID: 34589856
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
DOI: 10.1186/s12888-020-02523-1PMID: 32370778
Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/keap1 pathway.
DOI: 10.1016/j.ejmech.2020.112385PMID: 32402936
Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease.
DOI: 10.1038/s41380-020-0742-4PMID: 32372010
Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach.
DOI: 10.3390/ijms21093243PMID: 32375302
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
DOI: 10.1016/j.parkreldis.2020.04.012PMID: 32446176
Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.
DOI: 10.1007/s11011-020-00568-5PMID: 32363472
Changing faces of stress: Impact of heat and arsenite treatment on the composition of stress granules.
DOI: 10.1002/wrna.1596PMID: 32362075
Pharmacoeconomic Review Report: Safinamide (Onstryv): (Valeo Pharma Inc.): Indication: For add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing “OFF” episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD
PMID: 33231958
Clinical Review Report: Safinamide (Onstryv): (Valeo Pharma Inc.): Indication: For add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing “off” episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD
PMID: 33231957
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.